Morgan Stanley commented on Thermo Fischer Scientific TMO in a report released today. In the report, Morgan Stanley was positive in its assessment of the company.
Morgan Stanley writes, "The analyst day supports our positive thesis with 1) solid core business trends, 2) improving visibility on returning capital to shareholders, and 3) upside from the Dionex and Phadia integrations. With the investment debate focused on multiple expansion, the market's view of returns on recent acquisitions will drive the multiple, and we see room for expansion as evidence of strong synergy realization from Dionex and Phadia emerges to support a three-year EPS revenue CAGR of 17-20%. Finally, the capital deployment policy took a step forward in our view with Thermo for the first time incorporating future buybacks into guidance and committing ~50% of FCF to repurchases."
Morgan Stanley currently has an Overweight rating on Thermo Fischer Scientific and a price target of $64. Shares of TMO closed at $64.19, down $0.03 from the opening bell.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in